Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study: A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome

Impaired endogenous fibrinolysis is novel biomarker that can identify patients with ACS at increased cardiovascular risk. The addition of Very Low Dose Rivaroxaban (VLDR) to dual antiplatelet therapy has been shown to reduce cardiovascular events but at a cost of increased bleeding and is therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Gue, Ying X., Kanji, Rahim, Wellsted, David M., Srinivasan, Manivannan, Wyatt, Solange, Gorog, Diana A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969858/
https://www.ncbi.nlm.nih.gov/pubmed/31872349
http://dx.doi.org/10.1007/s11239-019-02014-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969858/
https://www.ncbi.nlm.nih.gov/pubmed/31872349
http://dx.doi.org/10.1007/s11239-019-02014-5

Ejemplares similares